NCT01856478 2026-01-12
LUX-Head&Neck 3: Afatinib (BIBW2992) Versus Methotrexate for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer After Platinum Based Chemotherapy
Boehringer Ingelheim
Phase 3 Completed
Clinical Trials
9 trialsNCT00003592 2023-06-22
Methotrexate Compared With Paclitaxel in Treating Patients With Advanced Head and Neck Cancer
Eastern Cooperative Oncology Group
Phase 3 Completed
NCT02105636 2022-10-05
Trial of Nivolumab vs Therapy of Investigator's Choice in Recurrent or Metastatic Head and Neck Carcinoma (CheckMate 141)
Bristol-Myers Squibb
Phase 3 Completed
NCT02347332 2019-03-05
Phase III Study of Vinflunine Plus Methotrexate Versus Methotrexate Alone in Patients With Head and Neck Cancer
Pierre Fabre Medicament
Phase 3 Completed
NCT01345682 2018-02-15
LUX-Head&Neck 1: A Phase III Trial of Afatinib (BIBW2992) Versus Methotrexate for the Treatment of Recurrent and/or Metastatic (R/M) Head and Neck Squamous Cell Cancer After Platinum Based Chemotherapy
Boehringer Ingelheim
Phase 3 Completed
NCT01528163 2017-06-14
RACATREX
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Phase 2 Completed
NCT00002476 2013-08-02
Radiation Therapy With or Without Chemotherapy in Treating Patients With Advanced Head and Neck Cancer
National Cancer Institute (NCI)
Phase 3 Completed
NCT00006033 2013-05-30
Interleukin-2 Gene or Methotrexate in Treating Patients With Recurrent or Refractory Stage III or Stage IV Head and Neck Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00206219 2011-01-27
Head and Neck Phase III Iressa Versus Methotrexate Refractory: Iressa Versus Methotrexate (IMEX)
AstraZeneca
Phase 3 Completed